Palivizumab for preterm infants. Is it worth it?

被引:26
作者
Embleton, ND [1 ]
Harkensee, C
Mckean, MC
机构
[1] Newcastle Univ, Newcastle Neonatal Serv, Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
[2] Newcastle Univ, Dept Child Hlth, Paediat Resp Unit, Newcastle Upon Tyne, Tyne & Wear, England
来源
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION | 2005年 / 90卷 / 04期
关键词
D O I
10.1136/adc.2004.058081
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Respiratory syncytial virus infection is an important cause of morbidity. Although palivizumab prophylaxis is widely used, it is uncertain whether the cost is justified. A systematic review was therefore performed of the safety, efficacy, and the likely cost effectiveness of prophylaxis for preterm infants in the United Kingdom using a standard search strategy. The only randomised controlled trial identified showed a reduction in hospital admission but no benefit on more serious outcomes. None of the United Kingdom cost studies showed economic benefit for palivizumab prophylaxis. New treatments are rarely cost effective, and, in the absence of a comprehensive economic assessment, continued use for high risk infants may appear justified.
引用
收藏
页码:F286 / F289
页数:4
相关论文
共 34 条
[1]  
Abramson JS, 2003, PEDIATRICS, V112, P1442
[2]   Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort [J].
Clark, SJ ;
Beresford, MW ;
Subhedar, NV ;
Shaw, NJ .
ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (04) :313-316
[3]  
Connor E, 1997, PEDIATRICS, V99, P93
[4]   The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area [J].
Deshpande, SA ;
Northern, V .
ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (12) :1065-1069
[5]   Guidelines for authors and peer reviewers of economic submissions to the BMJ [J].
Drummond, MF ;
Jefferson, TO .
BRITISH MEDICAL JOURNAL, 1996, 313 (7052) :275-283
[6]   Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].
Feltes, TF ;
Cabalka, AK ;
Meissner, C ;
Piazza, FM ;
Carlin, DA ;
Top, FH ;
Connor, EM ;
Sondheimer, HM .
JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540
[7]   Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection [J].
Greenough, A ;
Cox, S ;
Alexander, J ;
Lenney, W ;
Turnbull, F ;
Burgess, S ;
Chetcuti, PAJ ;
Shaw, NJ ;
Woods, A ;
Boorman, J ;
Coles, S ;
Turner, J .
ARCHIVES OF DISEASE IN CHILDHOOD, 2001, 85 (06) :463-468
[8]   Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial [J].
Groothius, JR .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (06) :628-630
[9]   Prevention of respiratory syncytial virus infection in infants - Palivizumab is effective but too expensive, and vaccines are unavailable as yet [J].
Handforth, J ;
Sharland, M ;
Friedland, JS .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7447) :1026-1027
[10]   Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants [J].
Joffe, S ;
Ray, GT ;
Escobar, GJ ;
Black, SB ;
Lieu, TA .
PEDIATRICS, 1999, 104 (03) :419-427